Clinical Trial Update: Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and efficacy of a coformulated pembrolizumab/quavonlimab plus lenvatinib in patients with advanced hepatocellular carcinoma h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)
• Quavonlimab (MK-1308)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED